Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03527108
Title Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fox Chase Cancer Center
Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.